Misonix Further Expands European Presence for Prostate Cancer Treatment with Visually Directed HIFU; Sonablate(R) 500 Now Available in Hungary.

FARMINGDALE, N.Y. -- Misonix, Inc. (Nasdaq: MSON), a developer of ultrasonic medical device technology for the treatment of cancer and other chronic health conditions, today announced the continued expansion of its European high intensity focused ultrasound ("HIFU") business with its entry into Hungary. The Company has formed a strategic relationship with Euro-OPEN KFT for the marketing of Visually Directed HIFU using the Sonablate(R) 500 ("SB500") for prostate cancer treatment in Hungary through direct equipment purchases or on a fee-per-use basis. The SB500 is a medical device developed by Focus Surgery, Inc. and manufactured and distributed in Europe by Misonix. Visually Directed HIFU is a new, non-invasive high intensity focused ultrasound technique developed by Focus Surgery and Misonix and available only with the SB500.

Misonix's pan-European HIFU strategy now includes access through in-country and cross border distribution channels into eleven countries in Europe. In addition to Hungary, these countries include some of the largest markets in Europe, such as France, Germany, and the United Kingdom. The United Kingdom is the most advanced markets in which Visually Directed HIFU has been made available, and it is the intent of Misonix to follow this successful model in other European countries.

Commenting on the continued execution of an important growth strategy, Michael A. McManus, Jr., President and Chief Executive Officer of Misonix, said, "This expansion into the Hungarian market represents another integral step to extend Misonix's reach in the European HIFU market. With a population of 10 million people, Hungarian physicians may now offer their patients treatment using our proprietary Visually Directed HIFU on the Sonablate 500. The new HIFU procedure will allow patients in Hungary the opportunity to benefit from access to far superior results to algorithm based treatments that require a surgical procedure in advance of the treatment (TURP).

"Together with Euro-OPEN KFT we will deliver the promise of HIFU to the Hungarian market that represents twice the results, with half the time and in only one procedure, unlike any other HIFU system available today in this market."

Commenting on the distribution agreement, Dr. Zsolt T. Nemeth, General Manager of Euro-OPEN KFT, said, "We are very excited about the prospect of delivering the promise of HIFU that has been proven in other European markets to patients and physicians in Hungary. The device is far superior to other technology we have reviewed."

About Misonix:

Misonix designs, develops, manufactures, and markets medical, scientific, and industrial ultrasonic equipment, laboratory safety equipment, and air pollution control products. Misonix's ultrasonic platform is the basis for several innovative medical technologies. Misonix has a minority equity position in Focus Surgery, Inc. which uses high intensity focused ultrasound technology to destroy deep-seated cancerous tissues without affecting surrounding healthy tissue. Addressing a combined market estimated to be in excess of $4 billion annually, Misonix's proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company's Web site at www.misonix.com.

With the exception of historical information contained in this press release, content herein may contain "forward looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. In particular, the Company may not be successful in its efforts with respect to strategic opportunities for its Laboratory and Scientific Division and the affect this activity may have on the other businesses within the Company. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, uncertainties as a result of research and development, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company's Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.